港股異動丨君實生物(1877.HK)大漲逾9% A股今日申購
格隆匯7月2日丨君實生物(1877.HK)大漲逾9%,報61港元,今年迄今累計漲幅約129%,有望挑戰上週五創下的歷史高點61.7港元,總市值達478億港元。君實生物此前發佈首次公開發行股票並在科創板上市發行公告,此次發行價格為55.50元/股,今日進行網上和網下申購。此外,君實生物本週一公佈,特瑞普利單抗注射液(商品名:拓益,產品代號:JS001)聯合侖伐替尼(LENVIMA)作為晚期肝細胞癌患者一線治療方案的III期臨牀研究(JS001-027-III-HCC研究)已完成首例患者給藥。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.